NO20040253L - Fremgangsmater for behandling av leverfibroser - Google Patents

Fremgangsmater for behandling av leverfibroser

Info

Publication number
NO20040253L
NO20040253L NO20040253A NO20040253A NO20040253L NO 20040253 L NO20040253 L NO 20040253L NO 20040253 A NO20040253 A NO 20040253A NO 20040253 A NO20040253 A NO 20040253A NO 20040253 L NO20040253 L NO 20040253L
Authority
NO
Norway
Prior art keywords
treatment
methods
liver fibrosis
fibrosis
liver
Prior art date
Application number
NO20040253A
Other languages
English (en)
Inventor
Henry H Hsu
Original Assignee
Intermune Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Pharmaceuticals Inc filed Critical Intermune Pharmaceuticals Inc
Publication of NO20040253L publication Critical patent/NO20040253L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20040253A 2001-07-20 2004-01-19 Fremgangsmater for behandling av leverfibroser NO20040253L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30701301P 2001-07-20 2001-07-20
PCT/US2002/021813 WO2003007981A1 (en) 2001-07-20 2002-07-09 Methods of treating liver fibrosis

Publications (1)

Publication Number Publication Date
NO20040253L true NO20040253L (no) 2004-03-19

Family

ID=23187860

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040253A NO20040253L (no) 2001-07-20 2004-01-19 Fremgangsmater for behandling av leverfibroser

Country Status (15)

Country Link
US (1) US20040241138A1 (no)
EP (1) EP1416953A4 (no)
JP (1) JP2004535464A (no)
KR (1) KR20040019069A (no)
CN (1) CN1549724A (no)
AR (1) AR047191A1 (no)
BR (1) BR0211336A (no)
CA (1) CA2453475A1 (no)
HU (1) HUP0401156A2 (no)
IL (1) IL159784A0 (no)
MX (1) MXPA04000630A (no)
NO (1) NO20040253L (no)
PL (1) PL367415A1 (no)
WO (1) WO2003007981A1 (no)
ZA (1) ZA200400319B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP2008528698A (ja) 2005-02-03 2008-07-31 インターシア セラピューティクス，インコーポレイティド 埋め込み可能なインターフェロン含有デバイス
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013040316A1 (en) 2011-09-16 2013-03-21 Galectin Therapeutics, Inc. Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
CA2811203C (en) 2011-10-21 2015-05-05 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2013184892A1 (en) 2012-06-06 2013-12-12 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US5362490A (en) * 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
CA2388005A1 (en) * 1999-09-28 2001-04-05 Joseph M. Cummins Low dose ifn-gamma for treatment of disease
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof

Also Published As

Publication number Publication date
ZA200400319B (en) 2005-03-30
HUP0401156A2 (hu) 2004-12-28
EP1416953A4 (en) 2005-11-09
CN1549724A (zh) 2004-11-24
EP1416953A1 (en) 2004-05-12
IL159784A0 (en) 2004-06-20
MXPA04000630A (es) 2005-02-17
CA2453475A1 (en) 2003-01-30
US20040241138A1 (en) 2004-12-02
BR0211336A (pt) 2004-09-28
PL367415A1 (en) 2005-02-21
JP2004535464A (ja) 2004-11-25
WO2003007981A1 (en) 2003-01-30
KR20040019069A (ko) 2004-03-04
AR047191A1 (es) 2006-01-11

Similar Documents

Publication Publication Date Title
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
NO20040097L (no) Kombinasjoner for behandling av inflammatoriske forstyrrelser
NO20050136D0 (no) Fremgangsmate for fremstilling av mikropartikler
CY2007029I1 (el) Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
NO20030012L (no) Fremgangsmåte for fremstilling av substituerte oktanoylamider
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
NO20041386L (no) Kombinasjoner for bahandling av immunoinflammatoriske forstyrrelser
IL159784A0 (en) Methods of treating liver fibrosis
NO20044916L (no) Preparater av sulfinylacetamid
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1206436T3 (da) Retinoider til behandling af emfysem
NO20040278L (no) Fremgangsmate for fremstilling av perindopril
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
NO20041968L (no) Anvendelse av cystationin
NO20035538D0 (no) Fremgangsmåte for fremstilling av zaleplon
NO20023445L (no) Fremgangsmåte for fremstilling av peptider
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20030515D0 (no) Fremgangsmåte for fremstilling av dinapsolin
NO20035136D0 (no) Fremgangsmåte til fremstilling av imipenem
NO20032769D0 (no) Kombinasjonsmetode for behandling av virale infeksjoner
FI20002290L (fi) Edeltävän keskinäisvaikutuksen päätöstakaisinkytketty korjain
DK1451177T3 (da) Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne